Summary
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals, RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death.
GlobalData epidemiologists provide a well-rounded, evidence-based analysis and forecast for the prophylactic populations for RSV in this report. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Several of the segmentations are further segmented by age, thereby providing a granular visualization of the RSV prophylactic and hospitalized market in the 8MM.
This report provides an overview of the risk factors, and global and historical trends for the RSV prophylactic population in the 8MM. It also includes a 10-year epidemiology forecast for the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population).
Scope
- The Respiratory Syncytial Virus (RSV) Epidemiology Report provides an overview of the global trends in risk factors for RSV in the seven major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
- The report includes a 10-year epidemiological forecast for the pediatric and adult populations that are at most risk for severe RSV infection and are therefore eligible for prophylactic treatment. This prophylactic population consists of: children born before 37 weeks of gestation (preterm population); preterm births with neonatal chronic lung disease (CLD); live births with hemodynamically significant congenital heart disease; boys 0-2 years old with Duchenne muscular dystrophy (DMD); children 0-2 years old with spinal muscular atrophy (SMA); pregnant women in their third trimester; and adults ≥ 55 years of age living in nursing homes or other long-term care institutions.
- The RSV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy
The RSV Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RSV market.
- Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RSV therapeutics in each of the markets
- Understand magnitude of RSV population by prophylactic markets
'
Table of Contents
1 Respiratory Syncytial Virus: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.1.1 Risk Factors and Comorbidities
2.2 Global and Historical Trends
2.3 Forecast Methodology
2.3.1 Sources
2.3.2 Forecast Assumptions and Methods
2.4 Epidemiological Forecast for RSV Prophylactic Population (2020-2030)
2.4.1 Number of Preterm Births by Gestational Age
2.4.2 Preterm Infants with CLD
2.4.3 Number of Live Births with Hemodynamically Significant Heart Disease and Congenital Lung Disease
2.4.4 Diagnosed Prevalent Cases of DMD
2.4.5 Number of Diagnosed Prevalent Cases of SMA
2.4.6 Number of Third-Trimester Pregnant Women
2.4.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions
2.5 Discussion
2.5.1 Epidemiological Forecast Insight
2.5.2 COVID-19 Impact
2.5.3 Limitations of the Analysis
2.5.4 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
Contact Us
List of Tables
Table 1: 8MM, Summary of the Prophylactic Population in 2020
Table 2: Summary of Newly Added Data Types
Table 3: Summary of Updated Data Types
Table 4: Risk Factors for Severe RSV
List of Figures
Figure 1: 8MM, Rate of Preterm Births (per 1,000 Live Births), 2020-2030
Figure 2: 8MM, Percentage of Adults Living in Long-Term Care, Ages ≥55 Years, 2020-2030
Figure 3: 8MM, Sources Used to Forecast the Number of Preterm Births
Figure 4: 8MM, Sources Used to Forecast the Number of Preterm Births with CLD
Figure 5: 8MM, Sources Used to Forecast the Number of Live Births with Hemodynamically Significant Heart Disease
Figure 6: 8MM, Sources Used to Forecast the Number of Live Births with Congenital Lung Disease
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of DMD
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SMA
Figure 9: 8MM, Sources Used to Forecast the Number of Third-Trimester Pregnancies
Figure 10: 8MM, Sources Used to Forecast the Number of Adults Living in Long-Term Care
Figure 11: 8MM, Number of Preterm Births by Gestational Age, N, 2020
Figure 12: 8MM, Number of Preterm Infants with CLD, N, 0-Year, 2020-2030
Figure 13: 8MM, Number of Live Births with Hemodynamically Significant Heart Disease and Congenital Lung Disease, 2020, 0-Year
Figure 14: 8MM, Diagnosed Prevalent Cases of DMD in Boys, Ages 0-2 Years, 2020-2030
Figure 15: 8MM, Diagnosed Prevalent Cases of SMA, Boys and Girls, Ages 0-2 Years, 2020-2030
Figure 16: 8MM, Number of Third-Trimester Pregnant Women, N, 2020-2030
Figure 17: 8MM, Number of Adults Living in Care Institutions, Ages ≥55 Years, N, 2020-2030
